Pharma merger promises sweeping IP shake-up
In-house counsel at merging pharma businesses Wyeth and Pfizer face an uncertain future when the new entity looks to slash costs and increase efficiency. But, as WTR has discovered, the drugs companies have other problems to consider: from opportunistic counterfeiting to merging two very different IP teams.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the WTR experts.